Fast, Accurate Test Aids in Detection of Lynch Syndrome

Colorectal cancer (CRC) is the third most commonly diagnosed cancer globally, with around 3-5% of cases attributed to Lynch syndrome - an uncommon hereditary cancer predisposition syndrome that elevates the risk of developing CRC. The current guidelines for cancer treatment emphasize the significance of testing for Mismatch Repair (MMR) status in all newly diagnosed CRCs as an initial screening procedure for Lynch syndrome. Immunohistochemistry (IHC), an increasingly prevalent clinical practice, is one of the suggested methods of testing.

Leica Biosystems’ (Nussloch, Germany) US FDA-cleared BOND MMR Antibody Panel now offers a high-performing IHC MMR option when screening CRC patients for identifying probable Lynch syndrome. The BOND MMR Antibody Panel is now available for clinical use on the BOND-III and BOND-MAX IHC automated instruments.

"Pathologists can utilize the Leica Biosystems BOND MMR Antibody Panel on the BOND-III for clear, accurate assessment of mismatch repair protein status in only 2.5 hours," said Dr. Robert Monroe, Chief Medical Officer at Leica Biosystems. "With this panel, clinicians can feel increased confidence in their MMR results."

"Leica Biosystems is proud to help our customers continue the fight against cancer through the fast, accurate results of the BOND MMR Antibody Panel, which provides the clinicians an important piece of the diagnostic puzzle in aiding the detection of Lynch syndrome," added Gustavo Perez-Fernandez, President of Leica Biosystems. "Our test enables targeted treatment for patients, supporting our mission of Advancing Cancer Diagnostics, Improving Lives."

Related Links:
Leica Biosystems